Home LiteratureArticle Details
PMID: 15919762 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection.

The Journal of pharmacology and experimental therapeutics ·Vol. 314 ·No. 3 ·2005-09-00 ·Pages 1386-92

Przyklenk K, Maynard M, Darling CE, Whittaker P

Abstract

Pretreatment with D-myo-inositol-1,4,5-trisphosphate hexasodium (D-myo-IP(3)), the sodium salt of the second messenger inositol 1,4,5-trisphosphate (IP(3)), is cardioprotective and triggers a reduction of infarct size comparable in magnitude to that obtained with ischemic preconditioning. However, this observation is enigmatic; whereas IP(3) signaling is conventionally initiated by receptor binding, IP(3) receptors are typically considered to be intracellular, and D-myo-IP(3) is membrane-impermeable. We propose that this paradox is explained by the presence of poorly characterized external IP(3) receptors and hypothesize that: 1) infarct size reduction with D-myo-IP(3) is receptor-mediated; and 2) communication via gap junctions and/or hemichannels is required to initiate this protection. To investigate the role of receptor binding, isolated buffer-perfused rabbit hearts underwent 30 min of coronary occlusion (CO) and 2 h of reflow. Prior to CO, hearts received no treatment (controls), D-myo-IP(3), L-myo-IP(3) (enantiomer not recognized by the IP(3) receptor), D-myo-IP(3) + the IP(3) receptor inhibitor xestospongin C (XeC), or XeC alone. Infarct size, assessed by tetrazolium staining, was reduced with D-myo-IP(3) treatment, whereas hearts that received L-myo-IP(3) or D-myo-IP(3) + XeC showed no protection. To evaluate the contribution of gap junctions/hemichannels, additional control and D-myo-IP(3)-treated cohorts received a 5-min infusion of heptanol or Gap 27, two structurally distinct gap junction inhibitors, administered at doses confirmed to attenuate intercellular transmission of a gap junction-permeable fluorescent dye. There was no infarct-sparing effect of D-myo-IP(3) in inhibitor-treated hearts. These data support the concepts that infarct size reduction with D-myo-IP(3) is triggered by receptor binding and that communication via gap junctions/hemichannels is involved in initiating this protection.

MeSH Terms
Animals Calcium Channels/physiology Gap Junctions/physiology Inositol 1,4,5-Trisphosphate/pharmacology,therapeutic use Inositol 1,4,5-Trisphosphate Receptors Myocardial Infarction/drug therapy Rabbits Receptors, Cytoplasmic and Nuclear/physiology
Chemicals
Calcium Channels Inositol 1,4,5-Trisphosphate Receptors Receptors, Cytoplasmic and Nuclear Inositol 1,4,5-Trisphosphate
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Przyklenk Karin
Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, 01655, USA. karin.przyklenk@umassmed.edu
Maynard Michelle
Darling Chad E
Whittaker Peter
Article Info
Journal
The Journal of pharmacology and experimental therapeutics
Abbr.
J Pharmacol Exp Ther
ISSN
0022-3565
Published
2005-09-00
Epub
2005-00-26
Pages
1386-92
Language
English
Region
United States
NLM ID
0376362
Subset
IM
Grants
NHLBI NIH HHS · R01-HL63713 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com